Experimental cancer drug trial halted early
NCT ID NCT05252416
First seen Jan 08, 2026 · Last updated May 16, 2026 · Updated 17 times
Summary
This early-stage study tested an experimental drug called BLU-222 in 50 people with advanced solid tumors (like breast, ovarian, or stomach cancer) that had stopped responding to standard treatments. The goal was to find a safe dose and see if the drug could shrink tumors. The study was terminated early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Columbia University Herbert Irving Comprehensive Cancer Center
New York, New York, 10032, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Florida Cancer Specialists
Sarasota, Florida, 34232, United States
-
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, 20133, Italy
-
Fondazione Policlinico Universitario A Gemelli-Rome
Rome, 00168, Italy
-
Henry Ford Health System
Detroit, Michigan, 48202, United States
-
Hospital of the Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111, United States
-
Instituto Europeo di Oncologia
Milan, 20141, Italy
-
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center (SKCCC)
Baltimore, Maryland, 21287, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Montefiore Medical Center
New York, New York, 10461, United States
-
OU Health Stephenson Cancer Center
Oklahoma City, Oklahoma, 73104, United States
-
St Bartholomew's Hospital
London, Middlesex, EC1A 7BE, United Kingdom
-
Stanford Women's Cancer Center
Stanford, California, 94305, United States
-
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California, 94158, United States
-
UNC Hospitals at Chapel Hill - The University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, 27514, United States
-
University of Arkansas for Medical Sciences
Little Rock, Arkansas, 72205, United States
-
University of Chicago Medical Center
Chicago, Illinois, 60637, United States
-
University of Utah - Huntsman Cancer Institute - PPDS
Salt Lake City, Utah, 84112, United States
-
University of Virginia Comprehensive Cancer Center
Charlottesville, Virginia, 22903, United States
-
Vanderbilt Breast Center at One Hundred Oaks
Nashville, Tennessee, 37204, United States
Conditions
Explore the condition pages connected to this study.